GSK

We’re committed to getting ahead of one of the most significant challenges to global health: #AntimicrobialResistance (AMR). That’s why we’re working with partners across innovation, access and antimicrobial stewardship to address it. This #WorldAMRAwarenessWeek we’re celebrating the achievement of our Worthing manufacturing site, who have been awarded the BSI Kitemark Certification for Minimized Risk of Antimicrobial Resistance. This international certification demonstrates our dedication to responsible antibiotic manufacturing. Our ambition is to have all our global antibiotic manufacturing sites certified by the end of 2026. Learn more: https://lnkd.in/etQU5Tez #WAAW2024

It's #WorldAMRAwarenessWeek! On Monday we joined the Fleming Initiative at London's Paddington Station to raise awareness on the risks of #AntimicrobialResistance. Thanks to everyone who stopped by our stand to share their thoughts and find out what we can all do to help prevent it. 👇 Check out the video to learn more. #WAAW2024

It’s #WorldCOPDDay. Did you know more than 391 million people are thought to have #COPD? This figure is expected to increase year on year which is why we believe prevention is the best strategy and are working to find solutions that get ahead of disease, prevent disease progression and where possible, reduce the number of people affected. This is why we’re applying our decades of expertise in respiratory medicine to deliver ambitious treatment goals. We want as many people with COPD as possible to achieve optimal symptom control, but we want to do more, we want to achieve disease stability and change the course of their disease. With our cutting-edge research, portfolio of vaccines and medicines, we’re working to protect people with COPD from infections and the related complications, reduce the risk of exacerbations, cumulative lung damage and hospitalisations and help to preserve their overall physical health. People with COPD deserve ambitious treatment goals and the opportunity to benefit from breathtaking innovation so they can simply take a breath with ease. 👇 https://gsk.to/3OhEYLR

We’re proud of our long-standing history of leadership in increasing access to medicines and our continued progress to help achieve this goal sees us rank second as one of two leading companies in this year’s Access to Medicine Index, an independent report led by the Access to Medicine Foundation. This means we have placed first or second in the Index since its inception in 2008. Our partnerships with governments, multilateral organisations and many others have been instrumental in driving this recognition and progress, which have seen us: 👉 supply 1.2 billion vaccine doses to Gavi, the Vaccine Alliance since 2010 to help protect the world’s most vulnerable children 👉 significantly increase access to innovative HIV medicines through collaborative partnerships 👉 improve access for new preventative interventions such as the first malaria vaccine for endemic countries, alongside our £1bn investment over ten years in R&D to help get ahead of diseases such as malaria and tuberculosis (TB) We remain committed to preventing and changing the course of disease through our innovation, while improving access to medicines and vaccines. Alongside our industry peers, partners and collaborators we’ll continue to address the impact of high burden diseases such as malaria, HIV and TB on health systems, individuals, their families and communities in lower-income countries. #ATMI24 #ChangeTheTrajectory

#AntimicrobialResistance (AMR) is a critical issue that demands our attention, so this #WorldAMRAwarenessWeek, we're raising awareness of the risks and giving you the knowledge you need to help prevent it. More than 39 million people could die of antibiotic-resistant infections between now and 2050. To get ahead of it, we must focus on preventing infections before they start. “We need to stop using antibacterials as Band-Aids and get out ahead by doing the hard things of providing clean food, clean water and vaccination for both viral and bacterial infections,” says Professor John Rex, founder of AMR Solutions. Find out more about the human impact of AMR – and how to prevent it in our article: https://gsk.to/3V0z5GF #WAAW2024

#News for #Investors and #Media: Today we announced headline results from a phase III study in cholestatic pruritus of primary biliary cholangitis (PBC). Learn more: https://gsk.to/3B0mPz0

We’re excited to be at this year’s American College of Rheumatology congress highlighting the importance of early intervention for those living with #lupus. When patients and doctors work together to treat lupus and lupus nephritis early with a goal of preserving kidney function, the risk of disease progression and organ damage can be reduced. Learn more about lupus and lupus nephritis and what doctors and patients can do to reduce the risk of organ damage: https://gsk.to/3YTDAUH #ACR24 #Lupus #LupusNephritis

Today, we kick off #WorldAMRAwarenessWeek, a crucial initiative to bring attention to one of the most pressing health issues of our time - #AntimicrobialResistance. Join us at London’s Paddington Station, near the historic spot where the first antibiotic was discovered. Our partner, the Fleming Initiative, will be by our side, engaging in conversations about how we can collectively combat the growing threat of resistant infections. Visit our stand to learn how you can make a difference. #WAAW2024

Ever wonder what it might be like to feel ants crawling all over your body? For those living with the cholestatic pruritus of primary biliary cholangitis (PBC), this sensation is all too familiar. Cholestatic pruritus is a persistent and often debilitating itch that can significantly impact the quality of life for individuals with PBC. Imagine the constant discomfort, the relentless urge to scratch, and the frustration of not finding relief. This is the reality for many who suffer from PBC. At GSK, we believe that through partnership and a commitment to patients, we can significantly impact the lives of those affected by liver diseases. Join us at #TLM24 as we present our latest research and advances in liver disease.

The world's first malaria vaccine, RTS,S, has now reached over 2 million children in sub-Saharan Africa. This wouldn't have been possible without the collaboration of organizations like PATH, World Health Organization, and partners across Africa. To mark this achievement, we’ve launched a new video series highlighting the vital role that partnerships played in the research and development of RTS,S. These videos shed light on why the support of African communities and research partners was crucial in adding this new tool to the malaria prevention toolbox in endemic countries. Learn more: https://gsk.to/4escxW9